USA-based Repros Therapeutics (Nasdaq: RPRX) saw its shares rocket more than 74% to $15.90 by early afternoon trading (March 28), after the company reported positive top-line results for the first pivotal study of Androxal, ZA-301, in the treatment of secondary hypogonadism.
Results for the Intent-to-Treat population met both co-primary endpoints mandated by the Food and Drug Administration on namely testosterone and sperm levels. The Intent-to-Treat population included all men randomized in the study whether or not they completed the study. 151 subjects were randomized into the study, 38 on placebo and 113 on Androxal.
Assuming that the drug is approved, it would join a market sector that already includes is AbbVie’s Androgel (testosterone gel), Auxilium Pharmaceuticals’ Testim (testosterone gel), and Eli Lilly’s Axiron (testosterone topical solution).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze